Status:
TERMINATED
Influence of Esmolol on a Closed-Loop Anesthesia System
Lead Sponsor:
Hopital Foch
Conditions:
Anesthesia
Eligibility:
MALE
18+ years
Phase:
PHASE3
Brief Summary
Main objective is to evaluate the sparing effect of esmolol on the required doses of propofol and remifentanil
Eligibility Criteria
Inclusion
- male patients scheduled for a general anesthesia
Exclusion
- age lower than 18 years
- allergy to propofol, or to soja or to peanuts, or to sufentanil, to remifentanil, or to morphine, or to a myorelaxant or to an excipient,
- any other history of anaphylactic reaction,
- hypersensibility to sufentanil, or to remifentanil, or to other derivate of fentanyl,
- hypersensibility to esmolol or to an excipient,
- history of central nervous system disease,
- patients receiving a psychotropic treatment or an agonist-antagonist opiate,
- hypovolemic patients,
- patients receiving a cardio-vascular treatment,
- patients with a pacemaker,
- expected bleeding more than 20% of the blood volume,
- simultaneous general and loco-regional anesthesia,
- patients suffering from asthma, COPD, trouble of the heart rhythm or conduction, cardiac insufficiency, cardiogenogenic shock, Prinzmetal syndrome, pheochromocytoma,
- patients with a heart rate less than 50/min and/or an arterial hypotension,
- neurosurgical act or any other which precludes an adequate positioning of the bispectral electrode.
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00922467
Start Date
June 1 2009
End Date
December 1 2011
Last Update
September 23 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Foch
Suresnes, France, 92151